New Issue: UBS prices $129,700 trigger autocallables linked to Biogen Idec

New York, Nov. 21 – UBS AG, London Branch priced $129,700 of 0% trigger autocallable optimization securities due Nov. 29, 2016 linked to the common stock of Biogen Idec Inc., according to a 424B2 filing with the Securities and Exchange Commission.

The notes will be called at par plus a call return of 15.98% per year if Biogen Idec shares close at or above the initial share price on any observation date, which occurs every year.

If the notes are not called and Biogen Idec shares finish at or above the trigger price, 90% of the initial share price, the payout at maturity will be par. Otherwise, investors will be exposed to the share price decline from the initial price.

UBS Financial Services Inc. and UBS Investment Bank are the underwriters.

Issuer:	UBS AG, London Branch
Issue:	Trigger autocallable optimization securities
Underlying stock:	Biogen Idec Inc. (Nasdaq: BIIB)
Amount:	$129,700
Maturity:	Nov. 29, 2016
Coupon:	0%
Price:	Par of $10.00
Payout at maturity:	Par if Biogen Idec shares finish at or above trigger price; otherwise, full exposure to share price decline
Call:	Automatically at par plus 15.98% per year if Biogen Idec shares close at or above initial share price on any observation date, which occurs every year
Initial share price:	$303.55
Trigger price:	$273.19, 90% of initial price
Pricing date:	Nov. 21
Settlement date:	Nov. 26
Underwriters:	UBS Financial Services Inc. and UBS Investment Bank
Fees:	2%
Cusip:	90272Q641

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.